Glysantis is an innovative biotechnology company developing nano-enabled Immunomodulatory therapeutics for the treatment of different cancers. Our platform nanotechnology (GLY-100) is built on a patented mono-disperse nanomaterial extracted from a natural source.
Our research programs are a collaborative effort between Glysantis and
researchers at The University of Guelph, Wilfrid Laurier University, The
University of Washington and Harvard University.